文献速递临床试验与 GCP

XINSORB生物可吸收支架植入后标准双联抗血小板治疗与延长双联抗血小板治疗的比较(SPARTA)试验:随机对照试验研究方案

The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-01-20

SPARTA试验为前瞻性随机平行组临床试验,旨在比较XINSORB生物可吸收支架植入后双联抗血小板治疗(DAPT)12个月与36个月的获益与风险。所有受试者术后先接受DAPT 12(±1)个月,无主要不良 cardiac 事件或大出血者随机接受额外24个月DAPT或单用阿司匹林。主要终点为主要不良 cardiac 事件复合终点及BARC 3或5型出血事件。

要点

  • 当前指南推荐生物可吸收支架植入后DAPT至少12个月,但延长DAPT与净临床获益的关系尚不清楚。
  • SPARTA试验计划纳入2106例仅接受XINSORB生物可吸收支架治疗的受试者。
  • 主要终点为包括全因死亡、任何心肌梗死和任何血运重建的主要不良 cardiac 事件复合终点,以及BARC 3或5型出血事件。

核心结论

  • 该试验旨在通过在接受XINSORB生物可吸收支架治疗的广泛患者人群中评估风险与获益的平衡,探讨将DAPT延长至3年的影响。

研究设计与样本

  • SPARTA试验为前瞻性、随机、平行组临床试验,计划纳入2106例仅接受XINSORB生物可吸收支架治疗的受试者,所有受试者术后接受DAPT 12(±1)个月,无主要不良 cardiac 事件或大出血者随机接受额外24个月DAPT或单用阿司匹林。

关键数值与推荐

  • 当前临床指南推荐生物可吸收支架植入后DAPT至少12个月。
  • 主要终点为主要不良 cardiac 事件复合终点(包括全因死亡、任何心肌梗死和任何血运重建)的发生率,以及BARC 3或5型出血事件。
  • 次要终点包括靶病变失败(心源性死亡、靶血管相关心肌梗死或缺血驱动的靶病变血运重建)、靶血管失败(心源性死亡、心肌梗死或缺血驱动的靶血管血运重建)、支架血栓形成和轻微出血事件。
  • 该试验计划纳入2106例仅接受XINSORB生物可吸收支架治疗的受试者。
  • 所有受试者术后接受DAPT 12(±1)个月,无主要不良 cardiac 事件或大出血者随机接受额外24个月DAPT或单用阿司匹林。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the standard of care after coronary stenting, including coronary stenting involving bioresorbable scaffolds (BRSs). Current clinical guidelines recommend at least 12 months of DAPT after BRS implantation. However, the correlation between prolonged DAPT and net clinical benefits remains unknown. METHODS: The SPARTA trial is designed to be a prospective, randomized, parallel-group, clinical trial. It aims to compare the benefits and risks of DAPT applied for either 12 or 36 months after XINSORB BRS implantation. The primary endpoints are the incidence of the composite endpoint of major adverse cardiac events (MACEs), including all-cause death, any myocardial infarction (MI), and all revascularizations, as well as Bleeding Academic Research Consortium Definition (BARC) type 3 or 5 bleeding events. The secondary endpoints of the study include the device-oriented composite endpoint of target lesion failure (defined as cardiac death, target vessel-related MI, or ischemia-driven target lesion revascularization), target vessel failure (defined as cardiac death, MI, or ischemia-driven target vessel revascularization), scaffold thrombosis, and minor bleeding events. This trial will enroll 2106 subjects treated with the XINSORB BRS only. All subjects will receive DAPT after the index procedure for 12 (± 1) months. Subjects without MACEs or major bleeding will be randomized to receive either 24 additional months of DAPT or aspirin alone. DISCUSSION: This trial is designed to investigate the impact of extending the duration of DAPT up to 3 years after XINSORB BRS implantation by investigating the balance of risks and benefits in a broad population of treated patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT04501900 . Registered on 6 August 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wu Y, Yin J, Li C, et al. The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial. Trials. 2023. PMID: 36670441. doi:10.1186/s13063-022-07028-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。